Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tarafenacin

Next Previous
X
Search
Drug Profile

Tarafenacin

Alternative Names: SVT-40776

Latest Information Update: 30 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SALVAT
  • Developer Kwang Dong Pharmaceutical; SALVAT
  • Class Antispasmodics; Quinuclidines
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Overactive bladder

Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 30 Jul 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, Australia, Czech Republic, Germany, Hungary, Netherlands, New Zealand, Russia, South Africa, South Korea and Spain (PO)
  • 09 Apr 2013 Efficacy and adverse events data from a phase IIb trial in Overactive bladder in South Korea released by SALVAT and Kwang Dong
  • 09 Apr 2013 SALVAT and Kwang Dong complete a phase IIb trial in Overactive bladder in South Korea (NCT01458197)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top